Observational Study on Efficacy of Alvesco(Ciclesonide) in Asthma Children and Adolescent in Real Practice
Information source: Handok Pharmaceuticals Co., Ltd.
Information obtained from ClinicalTrials.gov on December 08, 2011
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Asthma
Sponsored by: Handok Pharmaceuticals Co., Ltd.
This is a prospective, non-comparative, open, observational study.
Study design: Time Perspective: Prospective
Primary outcome: Asthma control day
Morning peak expiratory flow
The number of Reliever use
Asthma symptom score
Number of Participants with Adverse Events
Minimum age: 6 Years.
Maximum age: 18 Years.
- Children who is prescribed with ciclesonide for asthma
- Subjects with contraindications to ciclesonide use
- Subjects with clinically relevant concomitant disease that could compromise the
patient's safety should not be included in this study.
Locations and Contacts
Handok Pharmaceuticals, Seoul, Korea, Republic of; Recruiting
soo hyun yoon, Phone: 82-2-527-5151, Email: email@example.com
young yull Koh, Principal Investigator
Starting date: July 2010
Last updated: September 20, 2011